Skip to content
The Nexus
DossierENTITY

atopic dermatitis

Coverage of atopic dermatitis in the Nexus archive.

Earliest in view: May 27 · 14:33 UTCMost recent: Jun 22 · 12:50 UTC
Co-mentioned in this coverage
zumilokibarttopic2AbbVieorganization1Dupixenttopic1AstraZenecaorganization1FDAorganization1Blackstone Life Sciencesorganization1Apogee Therapeuticsorganization1Kaileraorganization1camizestranttopic1
Recent coverage
  • BUSINESSJun 22 · 12:50 UTCQUARTZ
    AbbVie is buying an eczema and asthma drug developer for almost $11 billion

    AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.

  • HEALTHMay 27 · 14:33 UTCSTAT NEWS
    STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful

    The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.